Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...
UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...
AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
Hosted on MSN2d
Cancer breakthrough: Daily pill which can DOUBLE survival time of lung cancer patients to be made available on NHSA breakthrough daily pill which doubles the survival time for certain lung cancer patients will now be routinely available on ...
GlobalData on MSN2d
J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLCThe Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...
A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...
In England, about 600 people will benefit from the daily pill that helps treat lung cancer as it becomes routinely available on the NHS.
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback